Preventive and therapeutic effects of Weifuchun Tablets on chronic atrophic gastritis in model rats
XIE Dong1,2,3* LIN Ling4* HAN Tao4 LU Lu1,2,3 YE Guan5 ZHANG Yeqing5 AN Yongtong5 SUN Mingyu1,2,3▲
1.Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
3.Shanghai University, Traditional Chinese Medicine, Shanghai 201203, China;
4.Prescription Teaching and Research Department, Basic Medical College, Shandong University of Traditional Chinese Medicine, Shandong Province, Ji′nan 250014, China;
5.Shanghai Pharmaceuticals Holding Co.,Ltd, Shanghai 201203, China
Abstract：Objective To explore the preventive and therapeutic effects of Weifuchun on chronic atrophic gastritis in model rats. Methods According to random stratification design, 50 Wistar rats were divided into 5 groups, with 10 rats in each group, namely the normal group (N group), the model group (M group), the high-dose Weifuchun group (WH group), the low-dose Weifuchun group (WL group), and the Vatacoenayme control group (VM group). N group was free to eat and drink water normal, and the other groups were fed 100 mg/L N-methyl-N1- nitro-N- nitrosoguanidine Aqueous Solution and 0.3 g/L Ranitidine feed. The rest groups were constructed by feeding with 100 mg/L N-methyl-N1-nitro-nitrosoguanidine Aqueous Solution and 0.3 g/L Ranitidine, and alternating gavage with 150 g/L sodium chloride solution at 56℃ and 30% ethanol according to the method of 10 mL/kg and combined with starvation and satiation disorder. After 4 weeks of modeling, drug therapy was given, WH group and WL group were respectively given gavage of 1.44 g/kg and 0.72 g/kg of Weifuchun, VM group was given gavage of 0.6 g/kg of Vatacoenayme, and N group was given gavage of 10 mL/kg of normal saline until death. The general situation, pepsin activity, pathological changes of gastric tissue and the changes in mRNA of genes related to inflammation and apoptosis in rats were observed. Results Compared with the M group, the weight gain of the drug group was improved to different degrees, while the WH group and WL group showed significant improvement; compared with the M group, the activity of pepsin in WH group and WL group increased to different degree (P ＜ 0.05), while the WH group increased significantly (P ＜ 0.01). Compared with the M group, the glandular atrophy in the drug group was decreased to different degrees, and compared with the WL group and VM group, the infiltration of lymphocytes, plasma cells and acid cells was decreased in the lamina propria of WH group; compared with the M group, the mRNA levels of nuclear factor-κB (NF-κB), tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), Bcl-2, cyclooxygenase-2 (COX-2), Caspase-3 and Caspase-8 in WH group and WL group were significantly down-regulated (P ＜ 0.05 or P ＜ 0.01) and the mRNA level of Bax in WH group was significantly up-regulated (P ＜ 0.01). Conclusion Weifuchun can enhance the activity of pepsin, and its therapeutic effect may be related to the inhibition of pro-inflammatory factors IL-1, TNF-α and COX-2, the down-regulation of the expression of NF-κB, and the regulation of cell apoptosis.
谢咚1,2,3* 林玲4* 韩涛4 陆璐1,2,3 叶冠5 张也青5 安泳潼5 孙明瑜1,2,3▲. 胃复春片对慢性萎缩性胃炎大鼠模型的防治作用研究[J]. 中国医药导报, 2019, 16(27): 13-17,32.
XIE Dong1,2,3* LIN Ling4* HAN Tao4 LU Lu1,2,3 YE Guan5 ZHANG Yeqing5 AN Yongtong5 SUN Mingyu1,2,3▲. Preventive and therapeutic effects of Weifuchun Tablets on chronic atrophic gastritis in model rats. 中国医药导报, 2019, 16(27): 13-17,32.
[1] Correa P. A human model of gastric carcinogenesis [J]. Cancer Res，1988，48（13）：3554-3560.
[2] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China [J]. CA Cancer J Clin，2016，66（2）：115-132.
[3] 张华颖，黄鑫宇，薛会光，等.慢性萎缩性胃炎发生胃癌的危险因素：一项长期随访研究[J].世界华人消化杂志，2018，26（31）：1812-1817.
[4] Deng H，Zhen H，Fu Z，et al. The antagonistic effect between STAT1 and Survivin and its clinical significance in gastric cancer [J]，Oncol Lett，2012，3（1）：193-199.
[5] Park EH，Kim YJ，Yamabe N，et al. Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell [J]. J Ginseng Res，2014，38（1）：22-27.
[6] 段李桃，党民卿，张星华，等.王道坤教授枳壳益胃汤异病同治举隅[J].陕西中医药大学学报，2017，40（2）：21-23，29.
[7] 滕建业.枳壳促进胃动力化学物质组的筛选及作用机理研究[D].沈阳：辽宁中医药大学，2011.
[8] 陈曦，赵亚红，张也青，等.胃复春的临床应用和现代研究进展[J].江西中医药，2016，47（9）：77-80.
[9] 徐明星，彭波，张昌欨，等.胃复春治疗慢性萎缩性胃炎临床研究[J].中医学报，2018，33（8）：1537-1541
[10] 曾东.胃复春联合麦滋林-S对幽门螺杆菌阴性的萎缩性胃炎126例疗效观察[J].中国中西医结合消化杂志，2015，23（8）：576-577.
[11] 林玲，韩涛，陆璐，等.慢性萎缩性胃炎及胃癌前病变动物模型的总结应用与评述[J].中国实验方剂学杂志，2019， 25（2）：220-227.
[12] Terasawa T，Nishida H，Kato K，et al. Prediction of gastric cancer development by serum pepsinogen test and helicobacter pylori seropositivity in eastern asians：a systematic reviewnd meta-analysis [J]. PLoS One，2014，9（10）：e109783.
[13] Janssen WJ，Henson PM. Cellular regulation of the inflammatory response [J]. Toxicol Pathol，2012，40（2）：166-173.
[14] 陈曦，孙明瑜，刘宁宁，等.胃癌癌前病变分子遗传学改变研究进展[J].中国医刊，2018，53（5）：477-481.
[15] 乔文，李娜，李长顺，等.IL-1β与人慢性胃炎的相关性研究[J].胃肠病学和肝病学杂志，2010，19（1）：47-48.
[16] 梁聚民，钱春花，权兰秋，等.胃癌、慢性萎缩性胃炎患者血清IL-6和TNF-α含量测定[J].第四军医大学学报，2007，28（23）：2204.
[17] 罗玉琴，吴开春，孙安华，等.浅表性胃炎、胃粘膜不典型增生及胃癌组织中COX-1、COX-2、iNOS表达的意义[J].中华消化杂志，2000，20（4）：223-226.
[18] 钟国新.针刺对慢性萎缩性胃炎模型大鼠NF-κB转导系统影响的研究[D].广州：广州中医药大学，2014.
[19] Yang LQ，Fang DC，Wang RQ，et al. Effect of NF-κB，survivin，Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand [J]. World J Gastroenterol，2004，10（1）：22-25.
[20] An FF，Liu YC，Zhang WW. Dihydroartemisinine enha-nces dictamnine-induced apoptosis via a caspase dependent pathway in human lung adenocarcinoma A549 cells [J]. Asian Pac J Cancer Prew，2013，14（10）：5895-5900.
[21] 李永乐，钱占红，郭志娟，等.中医药调控慢性萎缩性胃炎胃黏膜细胞凋亡的研究现状[J].世界科学技术-中医药现代化，2018，20（6）：1004-1009.
[22] 朱玉侠，赵明星，姜登鸽，等.抑癌基因p53、凋亡抑制基因Bcl-2、促凋亡基因Bax在胃癌及癌前病变中的表达[J].胃肠病学和肝病学杂志，2016，25（9）：1040-1043.
[23] 李铁军，魏书堂，李惠，等.安胃汤对慢性萎缩性胃炎模型大鼠细胞凋亡因子表达的影响[J].陕西中医，2018， 39（8）：987-990，994.
[24] 谭韡，周巍，罗和生，等.深在性囊性胃炎7例临床特点分析[J].疑难病杂志，2017，16（6）：627-629.
[25] 马立华，蔡柏.柴芍六君加味方抑制慢性萎缩性胃炎患者胃黏膜腺体萎缩及机制研究[J].西部中医药，2019， 32（7）：80-82.
[26] 韦玉娜，张静，王文杰，等.胃炎Ⅰ号对慢性萎缩性胃炎PCNA、Bcl-2和Bax表达的影响[J].世界华人消化杂志，2015，23（6）：944-948.
2019, Vol. 16 
京公网安备 11010502046598号